Source: PR Newswire

Press Release: Roivant : Immunovant to Present Phase 1 Clinical Trial Results at 2019 American Academy of Neurology Annual Meeting

NEW YORK and BASEL, Switzerland, May 9, 2019 /PRNewswire/ -- Immunovant, a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients living with debilitating autoimmune diseases, today announced that it will present the first detailed findings in...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Vivek Ramaswamy's photo - Founder & CEO of Roivant

Founder & CEO

Vivek Ramaswamy

CEO Approval Rating

83/100

Roivant Sciences researches and develops novel therapies for the treatment of neurological, urology and endocrine diseas... Read more